Suissa S, Blais L, Ernst P
Dept of Epidemiology and Biostatistics, Montreal General Hospital, McGill University, Quebec, Canada.
Eur Respir J. 1994 Sep;7(9):1602-9. doi: 10.1183/09031936.94.07091602.
The association between the use of inhaled beta-agonists by metered-dose inhaler and the risk of fatal or near-fatal asthma has been demonstrated. It shows that asthmatics who use one canister of beta-agonist per month more than the number used by other similar asthmatics have twice the risk of fatal or near-fatal asthma. The present investigation assesses the magnitude of this excess risk when an asthmatic increases his/her own monthly use of inhaled beta-agonists over time. From a previous nested case-control study of 129 deaths and near-deaths from asthma (cases) and 655 controls from a cohort of 12,301 asthmatics, the subset using at least 12 inhalers during the 12 month study period was identified (97 cases and 258 controls). A profile score, ranging 0-11, was formed to quantify the patterns of beta-agonist use over time for each subject, covering the entire spectrum extending from decreasing to increasing use. The relative risk was 15.2 (95% confidence interval (CI) 2.4-96.2) per unit increase of the profile score in subjects with a pattern of increasing beta-agonist use (profile score of 6.5 or more), but this relative risk was only 1.5 (95% CI 0.8-2.6) per unit when the profile score was less than 6.5 (non-increasing use). This relative risk was independent of the risk associated with the total quantity of beta-agonist use in the 12 month period, which remained around 1.6 (95% CI 1.3-2.0) per inhaler per month.(ABSTRACT TRUNCATED AT 250 WORDS)
定量吸入器使用吸入性β受体激动剂与致命性或接近致命性哮喘风险之间的关联已得到证实。结果显示,每月使用β受体激动剂吸入罐数量比其他类似哮喘患者多一罐的哮喘患者,发生致命性或接近致命性哮喘的风险要高出两倍。本研究评估了随着时间推移哮喘患者增加自身每月吸入性β受体激动剂使用量时,这种额外风险的程度。在之前一项针对12301名哮喘患者队列中的129例哮喘死亡和接近死亡病例(病例组)以及655名对照进行的巢式病例对照研究中,确定了在12个月研究期间使用至少12个吸入器的亚组(97例病例和258名对照)。为每个受试者形成了一个范围在0至11之间的概况评分,以量化β受体激动剂随时间的使用模式,涵盖从使用量减少到增加的整个范围。在β受体激动剂使用量呈增加模式(概况评分6.5或更高)的受试者中,概况评分每增加一个单位,相对风险为15.2(95%置信区间[CI] 2.4 - 96.2),但当概况评分小于6.5(非增加使用)时,每单位相对风险仅为1.5(95% CI 0.8 - 2.6)。这种相对风险与12个月期间β受体激动剂使用总量相关的风险无关,后者仍约为每月每个吸入器1.6(95% CI 1.3 - 2.0)。(摘要截断于250字)